Full Press Release Details
Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston.
IMMP
Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
Key Takeaway: Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)